Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line

被引:13
|
作者
Kang, Chung Hyo [1 ,2 ]
Kim, Yeongrin [1 ,3 ]
Lee, Heung Kyoung [1 ]
Lee, So Myoung [1 ]
Jeong, Hye Gwang [2 ]
Choi, Sang Un [1 ]
Park, Chi Hoon [1 ,3 ]
机构
[1] Korea Res Inst Chem Technol, Therapeut & Biotechnol Div, POB 107, Daejeon 34114, South Korea
[2] Chungnam Natl Univ, Coll Pharm, Daejeon 34134, South Korea
[3] Korea Univ Sci & Technol, Med Chem & Pharmacol, Daejeon 34113, South Korea
关键词
CD19; chimeric-antigen receptor; scFv; FMC63; leukemia;
D O I
10.3390/ijms21239163
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
CD19 is the most promising target for developing chimeric-antigen receptor (CAR) T cells against B-cell leukemic cancer. Currently, two CAR-T-cell products, Kymriah and Yescarta, are approved for leukemia patients, and various anti-CD19 CAR T cells are undergoing clinical trial. Most of these anti-CD19 CAR T cells use FMC63 single-chain variable fragments (scFvs) for binding CD19 expressed on the cancer cell surface. In this study, we screened several known CD19 scFvs for developing anti-CD19 CAR T cells. We used the KHYG-1 NK/T-cell line for screening of CD19 scFvs because it has advantages in terms of cell culture and gene transduction compared to primary T cells. Using our CAR construct backbone, we made anti-CD19 CAR constructs which each had CD19 scFvs including FMC63, B43, 25C1, BLY3, 4G7, HD37, HB12a, and HB12b, then made each anti-CD19 CAR KHYG-1 cells. Interestingly, only FMC63 CAR KHYG-1 and 4G7 CAR KHYG-1 efficiently lysed CD19-positive cell lines. In addition, in Jurkat cell line, only these two CAR Jurkat cell lines secreted IL-2 when co-cultured with CD19-positive cell line, NALM-6. Based on these results, we made FMC63 CAR T cells and 4G7 CAR T cells from PBMC. In in vitro lysis assay, 4G7 CAR T cells lysed CD19-positive cell line as well as FMC63 CAR T cells. In in vivo assay with NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice, 4G7 CAR T cells eradicated NALM-6 as potently as FMC63 CAR T cells. Therefore, we anticipate that 4G7 CAR T cells will show as good a result as FMC63 CAR T cells for B-cell leukemia patients.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 50 条
  • [1] Paving the road ahead for CD19 CAR T-cell therapy
    Nellan, Anandani
    Lee, Daniel W.
    CURRENT OPINION IN HEMATOLOGY, 2015, 22 (06) : 516 - 520
  • [2] CAR T cells: Building on the CD19 paradigm
    Globerson-Levin, Anat
    Riviere, Isabelle
    Eshhar, Zelig
    Sadelain, Michel
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2021, 51 (09) : 2151 - 2163
  • [3] CD19 CAR T cells: Prototypes for living drugs
    Sadelain, Michel
    Riviere, Isabelle
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2024, 208 (09): : 1288 - 1298
  • [4] Beyond CD19 CAR-T cells in lymphoma
    Leung, Wingchi K.
    Ayanambakkam, Adanma
    Heslop, Helen E.
    Hill, LaQuisa C.
    CURRENT OPINION IN IMMUNOLOGY, 2022, 74 : 46 - 52
  • [5] Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
    Fredon, Maxime
    Poussard, Margaux
    Biichle, Sabeha
    Bonnefoy, Francis
    Mantion, Charles-Frederic
    Seffar, Evan
    Renosi, Florian
    Bole-Richard, Elodie
    Boidot, Romain
    Chevrier, Sandrine
    Anna, Francois
    Loustau, Maria
    Caumartin, Julien
    Goncalves-Venturelli, Mathieu
    Robinet, Eric
    Saas, Philippe
    Deconinck, Eric
    Daguidau, Etienne
    Roussel, Xavier
    Godet, Yann
    Adotevi, Olivier
    Angelot-Delettre, Fanny
    Galaine, Jeanne
    Garnache-Ottou, Francine
    CANCER IMMUNOLOGY RESEARCH, 2024, 12 (08) : 1090 - 1107
  • [6] Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers
    Blanco, Belen
    Ramirez-Fernandez, Angel
    Bueno, Clara
    Argemi-Muntadas, Lidia
    Fuentes, Patricia
    Aguilar-Sopena, Oscar
    Gutierrez-Aguera, Francisco
    Zanetti, Samanta Romina
    Tapia-Galisteo, Antonio
    Diez-Alonso, Laura
    Segura-Tudela, Alejandro
    Castella, Maria
    Marzal, Berta
    Betriu, Sergi
    Harwood, Seandean L.
    Compte, Marta
    Lykkemark, Simon
    Erce-Llamazares, Ainhoa
    Rubio-Perez, Laura
    Jimenez-Reinoso, Anais
    Dominguez-Alonso, Carmen
    Neves, Maria
    Morales, Pablo
    Paz-Artal, Estela
    Guedan, Sonia
    Sanz, Laura
    Toribio, Maria L.
    Roda-Navarro, Pedro
    Juan, Manel
    Menendez, Pablo
    Alvarez-Vallina, Luis
    CANCER IMMUNOLOGY RESEARCH, 2022, 10 (04) : 498 - 511
  • [7] Efficacy and safety of humanized CD19 CAR-T as a salvage therapy for recurrent CNSL of B-ALL following murine CD19 CAR-T cell therapy
    Li, Xin
    Liu, Mei-Jing
    Mou, Nan
    Yang, Zhen-Xing
    Wang, Jia
    Mu, Juan
    Zhu, Hai-Bo
    Deng, Qi
    ONCOLOGY LETTERS, 2021, 22 (05)
  • [8] Should CD19 CAR-T Cells for ALL be Followed by Allogeneic Stem Cell
    Ramos, Carlos A.
    TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (01): : 1 - 2
  • [9] Complications after CD19+CAR T-Cell Therapy
    Penack, Olaf
    Koenecke, Christian
    CANCERS, 2020, 12 (11) : 1 - 17
  • [10] Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia
    Paszkiewicz, Paulina J.
    Fraessle, Simon P.
    Srivastava, Shivani
    Sommermeyer, Daniel
    Hudecek, Michael
    Drexler, Ingo
    Sadelain, Michel
    Liu, Lingfeng
    Jensen, Michael C.
    Riddell, Stanley R.
    Busch, Dirk H.
    JOURNAL OF CLINICAL INVESTIGATION, 2016, 126 (11) : 4262 - 4272